<DOC>
	<DOCNO>NCT02993471</DOCNO>
	<brief_summary>This study know `` drug interaction study . '' The purpose learn ixekizumab may affect blood level mixture commonly use drug ( caffeine , omeprazole , warfarin , dextromethorphan , midazolam ) metabolize cytochrome P450 . Each participant complete two study period . Participants take mixture commonly use drug ( plus vitamin K ) mouth 3 occasion ( prior treatment ixekizumab 1 12 week treatment ixekizumab ) . The study last 17 week , include follow-up . Screening must complete prior study start .</brief_summary>
	<brief_title>A Study Ixekizumab Participants With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Males females chronic moderate severe plaque psoriasis least 6 month candidate systemic therapy phototherapy Men woman childbearing potential must agree use reliable method birth control men may donate sperm duration study . Women must test negative pregnancy screen agree become pregnant study first normal period follow end study Have body mass index ( BMI ) 18.5 40.0 kilogram per square meter ( kg/m² ) , inclusive , screen Have great equal ( ≥ ) 10 percent body surface area ( BSA ) involvement screen first admission clinical research unit ( CRU ) Have Static Physicians Global Assessment ( sPGA ) score ≥3 Psoriasis Area Severity Index ( PASI ) score ≥12 screen first admission CRU Forms psoriasis chronic plaquetype Pregnant nursing ( lactate woman ) History ongoing , chronic recurrent infectious disease , evidence tuberculosis infection Have major surgery within 8 week prior first admission clinical research unit study Have history lymphoproliferative disease , sign symptoms lymphoproliferative disease , active history malignant disease , uncontrolled cerebrocardiovascular neuropsychiatric disease Require treatment cocktail drug inhibitor cytochrome P450 ( CYP ) 3A , CYP2C9 , CYP2D6 , CYP2C19 , CYP1A2 , inducer CYP3A CYP1A2 , rifampin ( inducer multiple CYPs ) substrates CYP3A , CYP2C9 , CYP2D6 , CYP2C19 , CYP1A2 narrow therapeutic index within 14 day prior first administration drug cocktail end Week 12 assessment Have know allergy hypersensitivity component study cocktail ixekizumab Have participate study ixekizumab , secukinumab brodalumab , prescribe ixekizumab secukinumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>